Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rusfertide in polycythemia vera
NL-OMON60244Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- May 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rusfertide in polycythemia vera (PV), sponsored by Takeda. Primary endpoints: Proportion of subjects achieving response from Week 20 through Week 32 and Absence of phlebotomy eligibility. Started May 2023; status: active, not recruiting.
02
Drugs
rusfertide
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NL-OMON60244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60244.